Kinesys Oncology: ESMO Congress, Copenhagen, 7-11 October 2016
Update on Lung Cancers, plus selected highlights in other tumours
Lung Cancer: http://emarketing.atalanta.uk.com/t/y-F1A2BEE45251C66C
RCC, Prostate, SCLC, Gastro-Oesophageal Cancers: http://emarketing.atalanta.uk.com/t/y-0F73DC93CC39BBDA
AstraZeneca: Selumetinib misses primary endpoint. Durvalumab: 80%, 6-month survival in Phase I / II study.
Merck’s Keytruda: Highly encouraging results in 1st and 2nd line treatment of squamous and non-squamous NSCLC.
BMS’ Opdivo: Disappointing update on 1st line treatment of NSCLC. Better results in bladder, kidney and head & neck cancer.
Roche: Positive results in 2nd / 3rd line NSCLC – PD-L1 vs non-PD-L1.
Renal Cell Carcinoma
Exelixis / Ipsen: Significant improvement in Phase II Metastatic RCC (renal cell carcinoma) trial vs sunitinib.
OncoGenex: Disappointing results in Phase III prostate cancer for custirsen.
Takeda: Alisertib prolongs PFS in 2nd line SCLC trial.
Ganymed: IMAB362 produced significant improvements in OS, PFS and ORR in gastric / gastro-oesophageal cancer patients.